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Sequence variation of antigenic proteins allows path-
ogens to evade antibody attack. The variable protein
commonly includes a hypervariable region (HVR),
which represents a key target for antibodies and is
therefore predicted to be immunodominant. To
understand the mechanism(s) of antibody evasion,
we analyzed the clinically important HVR-containing
M proteins of the human pathogen Streptococcus
pyogenes. Antibodies elicited by M proteins were
directed almost exclusively against the C-terminal
part and not against the N-terminal HVR. Similar
results were obtained for mice and humans with
invasive S. pyogenes infection. Nevertheless, only
anti-HVR antibodies protected efficiently against
infection, as shown by passive immunizations. The
HVR fused to an unrelated protein elicited no anti-
bodies, implying that it is inherently weakly immuno-
genic. These data indicate that the M protein HVR
evades antibody attack not only through antigenic
variation but also by weak immunogenicity, a para-
doxical observation that may apply to other HVR-
containing proteins.
INTRODUCTION
Among the mechanisms pathogens use to evade adaptive
immunity, antigenic variation has attracted particular interest,
because it occurs in numerous systems and is a major obstacle
to vaccine development (Lipsitch and O’Hagan, 2007; Deitsch
et al., 2009; Hensley et al., 2009). In its classical form, this
immune escape mechanism results from extensive sequence
variation in a surface protein, allowing the pathogen to evade
antibody attack. In many pathogens, the sequence variability is
generated during the course of a single infection, allowing
persistence in the individual host, but in other systems, new
mutants appear too rarely to allow immune escapewithin a single
individual. In the latter case, the pathogen may persist becauseCell Hosnew antigenic variants spread in the population, as exemplified
by influenza virus (Karlsson Hedestam et al., 2008). In both
scenarios, the variable protein commonly includes a hypervari-
able region (HVR), which represents a key target for antibodies.
Because HVRs are under selective pressure from host immu-
nity, they have been predicted to be immunodominant (Borst,
1991; Barbour and Restrepo, 2000; Forsell et al., 2009), implying
that they elicit stronger antibody responses than other parts of
the protein (Sercarz et al., 1993). This property could be favor-
able for the pathogen, if the HVR acts as a decoy, which diverts
the antibody response from other targets, as proposed to be the
case in some systems (Borst, 1991; Crane et al., 2006; Tobin
et al., 2008). However, a strong anti-HVR response should be
disadvantageous, if the HVR is a target for opsonizing antibodies
and/or has an important function that may be blocked by anti-
bodies (Johnsson et al., 1996; Baruch et al., 1997; Persson
et al., 2006; Karlsson Hedestam et al., 2008). This argument
and a study of streptococcal surface proteins (Sta˚lhammar-
Carlemalm et al., 2007) prompted us to analyze the paradoxical
hypothesis that an HVRmay escape antibodies not only through
antigenic variability, but also by eliciting a weak antibody
response. A weak anti-HVR response might be particularly
important when a microbial protein does not vary during a single
infection, because it could represent the onlymeans for the path-
ogen to escape anti-HVR attack in the individual host.
We studied the extracellular Gram-positive bacterium
Streptococcus pyogenes (group A streptococcus), a major path-
ogen that causes >500,000 deaths and >700 million throat and
skin infections each year (Carapetis et al., 2005). Among the viru-
lence factors ofS.pyogenes, particular interest hasbeen focused
on the fibrillar M protein, which is best known for its ability to
inhibit phagocytosis (Fischetti, 1989; Smeesters et al., 2010),
but promotes virulence also by other mechanisms (Waldemars-
son et al., 2009). This classical virulence factor has an N-terminal
HVR that exhibits extreme sequence divergence among strains
but is largely stable within a strain, allowing the identification of
200 distinct sequence types (Steer et al., 2009). Of note, the
HVR of an M protein does not function as a decoy, because it is
a target for opsonizing antibodies (Fischetti, 1989) and actively
contributes to virulence (Waldemarsson et al., 2009).
A consensus has emerged that protective anti-HVR antibodies
appear promptly in a host exposed to M protein (Fischetti, 1989;t & Microbe 10, 147–157, August 18, 2011 ª2011 Elsevier Inc. 147
Figure 1. Characterization of the M5 and M1 Proteins
(A) Schematic presentation of the processed forms of M5 andM1. These proteins have predicted molecular masses of 47.5 kDa and 46.7 kDa, respectively. Each
protein can be divided into a hypervariable region (HVR) and a region designatedBCW, comprised of B- and C-repeat regions and awall-spanning region (W). The
two HVRs have highly divergent sequences, as shown in the alignment, where identical amino acid residues are highlighted.
(B and C) Lack of antigenic cross-reactivity between the HVR and BCWparts of M5. In (B), purified proteins were separated by SDS-PAGE (left), and two identical
gels were subjected to western blot analysis with rabbit antisera against the HVR or BCW fragments, as indicated. Numbers indicate molecular mass in kDa. In
(C), rabbit antibodies to the HVR or the BCW were used to detect the corresponding protein immobilized in microtiter wells, and antibody binding was inhibited
with free HVR or BCW, as indicated. The data in (C) are based on three experiments and show mean values with SD.
(D) Phagocytosis assays in human blood, demonstrating that rabbit antisera to theHVRs promote type-specific opsonization ofS. pyogenes expressingM5 orM1
(strains M5 Manfredo and MGAS5005, respectively). Preimmune rabbit serum was used in the controls. Data are representative of two experiments. See also
Figure S1.
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reviews describe the HVR as immunodominant (Weiser and
Nahm, 2008; Georgousakis et al., 2009). However, the situation
is unclear because reports in the literature indicate that
the HVR may or may not be immunodominant (Beachey and
Seyer, 1986; Fischetti and Windels, 1988; Sta˚lhammar-Carle-
malm et al., 2007). Here, we used the clinically important M5
and M1 proteins to study whether M protein escapes protective
antibodies by eliciting a weak anti-HVR response. Our analysis
showed that the anti-HVR response was very limited, even in
humans with invasive S. pyogenes infection, while the C-terminal
part was immunodominant. These and other data indicate that
the HVR of an M protein escapes antibodies by two independent
mechanisms, antigenic variation and weak immunogenicity.
While the role of antigenic variation in immune escape is well
known, our study focuses interest on the ability of an HVR to
escape antibody attack by eliciting a weak response, i.e., by
being nonimmunodominant.
RESULTS
The Streptococcal M5 and M1 Proteins
The M5 and M1 proteins are epidemiologically associated with
rheumatic fever and streptococcal toxic shock syndrome,
respectively, the major life-threatening diseases caused by148 Cell Host & Microbe 10, 147–157, August 18, 2011 ª2011 ElseviS. pyogenes (Carapetis et al., 2005). Like other M proteins, M5
and M1 are fibrillar coiled-coil proteins, and they have similar
overall structure (Fischetti, 1989; Smeesters et al., 2010). Each
protein has an N-terminal HVR followed by a B-repeat region,
a C-repeat region, and a region (W) implicated in cell wall attach-
ment (Figure 1A). The extreme sequence divergence between
the HVRs of M5 and M1 is evident from an alignment (Figure 1A),
and the variability among HVRs of different M proteins is even
more striking in an alignment including four additional HVRs
(Figure S1A). For the work presented here, we divided the
sequences of M5 and M1 into two parts, designated HVR and
BCW, respectively, and used purified recombinant forms of the
two intact M proteins and their HVR and BCW fragments (Fig-
ure S1B). Good antisera were obtained when the M proteins
and their fragments were mixed with Freund’s adjuvant (FA)
and used to repeatedly immunize rabbits.
Because amajor goal of this study was to specifically measure
anti-HVR and anti-BCW antibodies, it was essential to exclude
cross-reactivity between these two parts within the M5 or
M1 protein. Analysis in the M5 system showed that rabbit anti-
bodies to the HVR and the BCW lacked cross-reactivity
(Figures 1B and 1C), and similar results were obtained in the
M1 system (Figure S1C). Thus, antibodies elicited by intact M5
orM1 can be specifically assigned to either region. Phagocytosis
assays with whole human blood showed that rabbit anti-HVRer Inc.
Figure 2. Prevention of Bacterial Growth by Anti-HVR Antibodies
(A) Protection against lethal infection. Three groups of mice (n = 19 per group) were passively vaccinated with the rabbit serum indicated and challenged with an
LD90 dose ofM5-expressingS. pyogenes. Survival after challenge was recorded during a 90 hr period. Pooled data from two experiments. Anti-HVR versus anti-
BCW, p < 0.0001; anti-HVR versus preimm, p < 0.0001; anti-BCW versus preimm, p = 0.05.
(B) Protection against growth in organs. Mice (n = 11–12 per group) were passively vaccinated with the rabbit sera indicated and challenged with a sublethal dose
of M5-expressing S. pyogenes. The mice were sacrificed 20 hr after challenge, followed by quantification of cfu in livers and spleens. Each dot represents one
animal, the rectangle represents 50% of the cfu values in each group, and the horizontal line indicates the median of the group. Significance is indicated as ***p <
0.001, ** p < 0.01, or n.s. (not significant).
(C) Phagocytosis assaywith whole human blood.S. pyogenesM5bacteria were opsonizedwith rabbit sera, diluted as indicated. The undiluted anti-HVR and anti-
BCW sera had the same titer, as determined with intact bacteria, allowing direct comparisons. Bacterial growth was determined after 3 hr and normalized against
the preimmune sample (defined as 100). Mean values with SD for three experiments with two different blood donors. See also Figure S2.
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that theHVR fragments used here contained biologically relevant
epitopes and elicited antibodies with the expected specificity
(Figure 1D).
Only Anti-HVR Antibodies Efficiently Prevent
Bacterial Growth
Our studies were based on the assumption that antibodies to the
HVR of an M protein are particularly important for protection
against S. pyogenes infection, implying that it is essential for the
bacteria to escape attack by such antibodies. It may appear
self-evident that anti-HVR antibodies would protect against
infection with the homologous S. pyogenes strain and would be
more efficient than antibodies to the C-terminal part, but the
evidence that anti-HVR antibodies protect in vivo is limited (Hall
et al., 2004; Penfound et al., 2010). Moreover, even antibodies
to the C-terminal part might confer protection (Fischetti, 1989;
Pandey et al., 2009). It was therefore important to directly com-
pare the protective ability of polyclonal antibodies elicited by
the HVR and the C-terminal region, respectively. We performed
such analysis employing amousemodel of passive immunization
and the M5-expressing S. pyogenes strain (Figures 2A and 2B).Cell HosThe rabbit anti-HVR and anti-BCW sera used for passive
immunizations were adjusted to have the same titer against
whole M5-expressing bacteria, allowing direct comparison of
their protective capacities (data not shown). The anti-HVR anti-
bodies protected efficiently against lethal infection, while anti-
BCW antibodies had little or no protective effect (Figure 2A).
Moreover, anti-HVR antibodies, but not anti-BCW antibodies,
strongly inhibited bacterial growth in livers and spleens (Fig-
ure 2B). In agreement with these in vivo data, only anti-HVR anti-
bodies promoted phagocytosis ex vivo, in whole human blood
(Figure 2C). Rabbit antiserum to intact M5 (raised by repeated
immunization with the M5 protein mixed with FA) also promoted
phagocytosis, but when this antiserumwas depleted of anti-HVR
antibodies its opsonizing capacity was lost (Figure S2). Thus,
it is particularly important for S. pyogenes to evade anti-HVR
antibodies.
The HVRs of the Intact M5 and M1 Proteins Elicit Weak
Antibody Responses
To analyze whether the HVR present in an intact M protein is
weakly immunogenic, as compared to the C-terminal part, we
analyzed the antibody response in mice immunized with puret & Microbe 10, 147–157, August 18, 2011 ª2011 Elsevier Inc. 149
Figure 3. The HVRs of the M5 and M1 Proteins Elicit Weak Antibody Responses
(A) Upper two panels: PureM5 or M1,mixed with alum, was used to immunizemice (n = 11 for M5, n = 9 for M1). Sera were analyzed for antibodies to the HVR and
BCW fragments and to intact M protein. The weak anti-HVR response is emphasized by blue shading. Lower two panels: As in the upper panels, but M protein
mixed with FA was used for the immunizations (n = 7 for M5 and n = 7 for M1).
(B) Inhibition tests. One anti-M5 and one anti-M1 serum raised with alum (fromA) were used to detect the correspondingM protein immobilized inmicrotiter wells,
and binding was inhibited with the proteins indicated. Similar data were obtained with a second antiserum of each type.
(C) Western blot analysis with antisera from mice immunized with M5 and alum or M5 and FA, as indicated. Similar results were obtained with two sera of each
type.
(D) Long-term immunizations. Two groups of mice (n = 6) were immunized with M5 (20 mg) mixed with alum. Each group received one booster (10 mg) after
4 weeks, and the second group received an additional booster (10 mg) 10 weeks later. All mice were bled 16 weeks after the initial immunization. Antibody titers
against M5 and its HVR and BCW fragments were determined. The data showmean values with SD for all mice within a group (A and D) or for three experiments
with one serum (B). See also Figure S3.
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FA, the immunizations were performed with alum as the adju-
vant. Interestingly, these mouse sera reacted with the corre-
sponding M protein and its BCW fragment, but hardly at all
with the HVR fragment (Figure 3A, upper panels). Indeed, <1%
of the antibodies elicited by the intact M protein reacted with
the HVR. These assays had been optimized to allow accurate
detection of anti-HVR and anti-BCW antibodies, indicating that150 Cell Host & Microbe 10, 147–157, August 18, 2011 ª2011 Elsevithe lack of detection of anti-HVR antibodies was not due to an
inability to detect such antibodies (Figures S3A–S3D).
The binding tests indicated that only a small fraction of the
antibodies elicited by intact M proteins was directed against
the HVR. However, these binding tests employed the isolated
HVR fragment for detection of anti-HVR antibodies, and the
results did not exclude that the HVR part of the intact M protein
elicited antibodies against epitopes not present in the isolateder Inc.
Figure 4. Weak Anti-HVR Response in Mice Infected with S. pyogenes
(A) Mice (n = 6) were infected with a sublethal dose of M5-expressing S. pyogenes, and sera were recovered after 4 weeks. Antibody titers against M5 and its HVR
and BCW parts were determined. Mean values with SD for all mice.
(B) Western blot analysis with the proteins indicated and serum from one infected mouse. Similar results were obtained with serum from a second mouse.
(C) Inhibition tests with antiserum from one infected mouse. This antiserum was used to detect immobilized M5 protein, and binding was inhibited by the addition
of M5 or its HVR and BCW fragments, as indicated. The data represent mean values from three experiments, with SD. Similar results were obtained with antisera
from two other infected mice.
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been strongly underestimated. This explanation was excluded
by the demonstration that antibodies elicited by intact M5 or
M1 were inhibited virtually completely by the corresponding
BCW fragment, but not by the HVR fragment (Figure 3B). Finally,
western blot analysis in the M5 system demonstrated that
mouse antiserum elicited by intact M5 and alum detected the
BCW but not the HVR (Figure 3C, left and middle panels).
Thus, analysis by three different methods indicated that mouse
antibodies elicited by M5 or M1, mixed with alum, were directed
almost exclusively against the BCW region, while the HVR eli-
cited a very weak response. Of note, the M proteins used for
immunization had the expected sizes andN-terminal sequences,
demonstrating that the lack of anti-HVR response was not due to
degradation of the HVR (Figure S1B).
To analyze whether the poor anti-HVR response could be ex-
plained by delayed appearance of anti-HVR antibodies, we used
the M5 protein. Mice immunized with pure M5 and alum were
given one or two boosters and bled 16 weeks after the initial
immunization. Also in these mice, <1% of the antibodies were
directed against the HVR, demonstrating that the anti-HVR
response is not just delayed (Figure 3D). Although the use of
two boosters increased overall titers, the fraction of antibodies
directed against the HVR remained very low. Preimmune mouse
serum virtually lacked reactivity with M proteins (data not
shown), indicating that the selective production of anti-BCW
antibodies in immunized mice did not reflect a recall response,
following previous exposure to an M protein with similar BCW
region but different HVR.
A Strong Adjuvant Selectively Enhances
the Anti-HVR Response
The weak anti-HVR response after immunization with an M
protein is not readily reconciled with the common assumption
that S. pyogenes infection results in the formation of type-
specific and protective anti-HVR antibodies (Lancefield, 1962;
Fischetti, 1989). A possible explanation for this apparent contra-
diction was provided by the observation that the strongly
immunostimulatory FA caused selective enhancement of theCell Hosanti-HVR response in mice immunized with intact M5 or M1, as
demonstrated in direct binding tests (Figure 3A, lower panels)
and by western blot in the M5 system (Figure 3C, right panel).
These mice had been immunized twice, once with complete
FA and once with incomplete FA. Also, under these conditions
the anti-HVR responsewasweaker than the anti-BCW response,
but the difference was considerably smaller than in immuniza-
tions with alum. Indeed, the fraction of antibodies directed
against the HVR increased >10-fold when FA was used.
However, the anti-HVR response in thesemice was not sufficient
to protect against infection (Figure S3E), suggesting that
a protective anti-HVR response may require prolonged antigen
exposure and inflammation.
In contrast to intact M5 and M1 in combination with FA, which
enhanced the anti-HVR response, the isolated HVRs of these M
proteins in combination with FA did not elicit antibody responses
in mice (data not shown). The reason for this lack of antibody
response in mice is not known, but a simple explanation could
be that the isolated HVRs lacked relevant T cell epitopes.
The HVR Is Weakly Immunogenic in Mice and Humans
Infected with S. pyogenes
To analyze whether the HVR of an M protein is weakly immuno-
genic during S. pyogenes infection, we analyzed experimentally
infectedmice and humanswith invasive infection. Themice were
infected with a sublethal dose of the M5-expressing strain, and
sera recovered after 4 weeks were analyzed for antibodies to
the HVR and the BCW region of M5. The antibodies showed
very low reactivity with the HVR, as demonstrated by direct
binding tests and western blot analysis, but reacted well with
the BCW and intact M5 protein (Figures 4A and 4B). Inhibition
experiments confirmed that the antibodies were directed almost
exclusively against the BCW (Figure 4C). In this inhibition anal-
ysis, the BCW fragment caused more efficient inhibition than
intact M5, for unknown reasons, but both proteins caused virtu-
ally complete inhibition. Thus, the HVR of M5 elicits a weak anti-
body response during experimental infection.
The antibody response to M protein in infected humans was
studied with sera from patients with invasive infection causedt & Microbe 10, 147–157, August 18, 2011 ª2011 Elsevier Inc. 151
Figure 5. Analysis of Sera from Humans with Invasive S. pyogenes Infection
(A) Acute and convalescent sera from two patients with invasive S. pyogenes M1 infection were analyzed for reactivity with immobilized full-length M1.
(B) Antibody binding assays with the two convalescent sera and the immobilized antigens indicated.
(C) Western blot analysis with the two convalescent sera.
(D) Inhibition assays with the two convalescent sera. The two sera were used to detect immobilizedM1, and binding was inhibited by the addition of M1 or its HVR
and BCW fragments, as indicated. Because the human sera were available in limited amounts, the tests could only be performed at one concentration of inhibitor
(6 mM), chosen on the basis of a preliminary experiment.
(E) Dot blot analysis with convalescent serum from patient I. This serum reacted with intact M1, derived from strain SF370, but very poorly with the corresponding
M1-HVR or with the HVR of M1 in strain MGAS5005. The latter HVR is identical to that in the patient isolates and diverges from the SF370 sequence at one
position. The HVRs were used as GST fusions. Similar results were obtained with serum from patient II. The data in (A), (B), and (D) represent mean values with SD
from three experiments.
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treated with antibiotics, including penicillin, upon admission.
Accurate analysis made it essential to have access to the
S. pyogenes strain causing the infection and to paired sera,
i.e., acute and convalescent serum. Characterization of the
strain was necessary to ensure that it encoded the M1 protein,
while comparison of paired sera made it possible to analyze
whether the patient had responded to the current infection.
Such material was available for six patients, and two of them
showed a clear increase in anti-M1 titer between the acute and
convalescent samples, unequivocally showing that the antibody
response was associated with the M1 infection (Figure 5A). The
convalescent sera from these two patients reacted strongly with
the BCW but not the HVR of M1, as demonstrated by direct
binding tests, western blots, and inhibition tests (Figures 5B–
5D). The M1-HVR in the patient strains diverged at one amino
acid position from theM1-HVR fragment used in the immunolog-
ical tests, but this small difference did not affect the reactivity
with patient sera, as shown in a dot blot analysis with the relevant
constructs (Figure 5E). Thus, the HVR of an M protein is poorly
immunogenic even during invasive infection in humans.
The HVR Remains Weakly Immunogenic when Fused
to an Unrelated Protein
The weak antibody response elicited by the HVR of an M protein
could reflect an inherent property of this region. Alternatively,152 Cell Host & Microbe 10, 147–157, August 18, 2011 ª2011 Elsevithe weak anti-HVR response could reflect inhibition by the
adjacent BCW region. To distinguish between these two alterna-
tives, we analyzed the antibody response to fusion proteins, in
which the HVR of M5 had been fused to immunogenic regions
derived from other streptococcal surface proteins. In these
fusion proteins, the HVR was located at the N-terminal end, as
in M proteins (Figure 6A). If the M5-HVR is inherently weakly
immunogenic, one would expect such a fusion protein to elicit
a weak anti-HVR response, but if the BCW region is inhibitory,
the fusion protein would probably elicit a good anti-HVR
response. Two different C-terminal fusion partners were studied,
to ensure that unequivocal results would be obtained.
One of the fusion partners, designated B6, was derived
from the N-terminal B6 region of the S. agalactiae b protein
(Hede´n et al., 1991), while the other fusion partner, referred to
here as NN, was derived from the N-terminal regions of the
S. agalactiae Rib and a proteins (Sta˚lhammar-Carlemalm et al.,
2007). These fusion partners were used, because both B6 and
NN were known to elicit good antibody responses in mice,
when administered with alum (Sta˚lhammar-Carlemalm et al.,
2007; our unpublished data). Of note, the size of the two fusion
proteins was similar to that of an M protein. As expected, each
fusion protein reacted with rabbit antisera raised against the
M5-HVR or the fusion partner (Figures S4A and S4B). This
analysis also showed that the M5-HVR did not cross-react with
any of the fusion partners, implying that antibodies elicited byer Inc.
Figure 6. Antibody Response to Fusion Proteins
(A) Schematic presentation of two fusion proteins derived from the M5-HVR and unrelated immunogenic protein regions. These fusion proteins are designated
(M5-HVR)-B6 and (M5-HVR)-NN, respectively. The B6 region was derived from the N-terminal part of the S. agalactiae b protein, while the NN region was derived
from the N-terminal parts of the S. agalactiae Rib and a proteins.
(B) C3H/HeNmice (n = 10) immunized with the fusion protein (M5-HVR)-B6 mixed with alum were analyzed for antibody response to the intact fusion protein and
its two constituent parts, as indicated.
(C) Inhibition test. Antiserum from amouse immunized with (M5-HVR)-B6was used to detect this protein immobilized inmicrotiter wells, and binding was inhibited
with the proteins indicated. Similar data were obtained with antiserum from a second mouse.
(D) Western blot analysis with an antiserum from a mouse immunized with (M5-HVR)-B6. Similar results were obtained with a second antiserum.
(E–G) Same analysis as in (B)–(D), except that the antigen used was the fusion protein (M5-HVR)-NN. For (E), 11 sera were analyzed. For (F) and (G), similar results
were obtained with two different sera. The data showmean values with SD for all mice within a group (B and E) or for three experiments with one serum (C and F).
See also Figure S4.
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or the C-terminal part.
The two fusion proteins, (M5-HVR)-B6 and (M5-HVR)-NN, eli-
cited good antibody responses when mixed with alum and used
to immunize mice. These antibody responses were directed
exclusively against the C-terminal fusion partner, as shown by
direct binding tests, inhibition tests, and western blot analysis
(Figures 6B–6G). Remarkably, the HVR was even less immuno-
genic in the fusion proteins than in intact M5 (Figure 3A). This
lack of anti-HVR response could not be explained by loss of
the HVR from the recombinant fusion proteins, because theyCell Hosreacted with anti-HVR serum and had the expected N-terminal
sequences (Figures S4A and S4B). Moreover, the result was
not dependent on mouse strain used, because equally weak
anti-HVR responses were elicited in C3H/HeN mice (Figures
6B and 6E) and in C57BL/6 mice (Figures S4C and S4D). Finally,
the dominating response to the C-terminal fusion partner could
not be explained as a recall response, reflecting previous expo-
sure to the fusion partner, because preimmune mouse serum
lacked antibodies to the B6 and NN proteins (data not shown).
Together, these data indicate that the HVR of an M protein is
inherently weakly immunogenic.t & Microbe 10, 147–157, August 18, 2011 ª2011 Elsevier Inc. 153
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The work described here was based on the paradoxical hypoth-
esis that the HVR of an M protein may escape antibody attack,
not only through antigenic variation but also by eliciting a weak
antibody response. Using the well-known M5 and M1 proteins
and a variety of experimental conditions, we found strong
evidence for the hypothesis. Remarkably, even life-threatening
invasive infection in humans was insufficient to elicit a good
anti-HVR response, as demonstrated for patients infected with
M1-expressing S. pyogenes. The biological relevance of these
findings was supported by studies with hyperimmune rabbit
antisera, raised against the isolated HVR or C-terminal part of
M5. While the anti-HVR antibodies prevented bacterial growth
in infected mice and promoted opsonization in phagocytosis
tests, this was not the case for antibodies to the C-terminal
part. Thus, bacterial virulence would be promoted by a mecha-
nism that limits the formation of anti-HVR antibodies and makes
the C-terminal part immunodominant.
The phenomenon of immunodominance signifies that an
immune response is limited to a proportion of the potential deter-
minants on an antigen (Sercarz et al., 1993). This phenomenon
has been extensively studied for T cell responses, where it
reflects the fact that only a small fraction of all possible peptides
derived from a protein antigen are presented on MHCmolecules
and trigger T cell responses (Sant et al., 2007). However, the lack
of anti-HVR response studied here cannot be explained by
absence of T cell epitopes in the HVRs, because the intact M5
and M1 proteins contain T cell epitopes, as indicated by the
formation of antibodies to the C-terminal parts. According to
standard models, these T cell epitopes may provide help to
any B cell epitope in the proteins, including those in the HVRs.
Thus, the lack of anti-HVR response does not reflect lack of
T cell help butmost likely reflects lack of activation of the relevant
B cells. This conclusion focuses interest on the poorly under-
stood mechanisms that promote immunodominance, or lack of
immunodominance, at the B cell level (Wicker et al., 1984;
Sercarz et al., 1993; Nakra et al., 2000).
For the HVR of an M protein, we considered two possible
explanations for its lack of immunodominance at the B cell level.
In one scenario, the C-terminal region actively interferes with the
antibody response to the adjacent HVR, and in another scenario
the HVR is inherently weakly immunogenic. Studies of two
different fusion proteins, in which the M5-HVR was combined
with unrelated immunogenic protein regions, strongly suggested
that weak immunogenicity is an inherent property of the HVR, at
least when it is located N-terminally, as in an M protein. This
conclusion does not exclude that anHVRmight elicit a good anti-
body response under other conditions. For example, the HVR
fragments of M5 and M1 elicited good antibody responses in
rabbits, when mixed with FA, and multivalent HVR proteins
may elicit protective antibody responses (Hall et al., 2004;
Penfound et al., 2010).
How can weak immunogenicity be an inherent property of the
HVR in anM protein? Properties that may contribute include lack
of defined tertiary structure (Dey et al., 2009), selective sensitivity
to proteases (Raeder et al., 1998), and affinity for a host compo-
nent that interferes with antibody formation (Beernink et al.,
2011). It is also conceivable that immunological tolerance154 Cell Host & Microbe 10, 147–157, August 18, 2011 ª2011 Elsevicontributes to the weak immunogenicity, reflecting similarity
between the HVR and a host component, but this hypothesis is
not readily reconciled with the extreme sequence divergence
among HVRs. Moreover, it is unlikely that a modification such
as glycosylation can explain the weak immunogenicity of the
HVR, because a modification would not have been present in
the recombinant proteins used here. Of note, any explanation
for the weak immunogenicity must be compatible with the
finding that the HVR plays a key role in virulence during the early
stages of an infection (Waldemarsson et al., 2009).
The paradoxical finding that the HVR is weakly immunogenic
raises the question how the sequence divergence among
different HVRs has evolved. A clue to this problem was provided
by the observation that anti-HVR responses were selectively
enhanced in mice immunized with intact M protein and FA, an
adjuvant that causes a robust inflammatory response. Strong
inflammation may also accompany an S. pyogenes infection
(Cunningham, 2000), resulting in conditions that gradually favor
the appearance of protective anti-HVR responses and the selec-
tion of antigenic escape variants. This argument does not contra-
dict the fact that the existing HVRs are largely stable, because
they may have been selected as the most fit ones, making
them subject to strong negative selection and favoring sequence
conservation (Persson et al., 2006; Lipsitch and O’Hagan, 2007).
The hypothesis that a protective anti-HVR response appears
slowly and requires a robust inflammatory response is supported
by early observations on rabbits immunized with M protein-con-
taining extracts (Hirst and Lancefield, 1939) and by studies of
humans with S. pyogenes infection (Denny et al., 1957; Siegel
et al., 1961). The studies of humans showed that type-specific
antibodies did not appear in patients cured of the infection by
treatment with penicillin and appeared only slowly in patients
with prolonged infection. When this work was published, it was
not known that M proteins have an HVR, and the data did not
exclude that all antibodies to M protein appear slowly. However,
our findings indicate that only the anti-HVR response requires
prolonged antigen exposure and inflammation. Thus, our data
are fully compatible with the early studies in humans and provide
a molecular insight not previously available. Our data are also
compatible with the very few studies in which protective immu-
nity was analyzed in mice immunized with an intact M protein.
One of these studies reported that intranasal (i.n.) immunization
with M1 elicited protection against i.n. challenge with an M1
strain (Siegert et al., 2006). Although interesting, the significance
of this finding is unclear, because i.n immunization may elicit
antibody-independent cellular immunity to infection (Basset
et al., 2007;Wang et al., 2010). In another study,mice immunized
with pure M1 were barely protected against lethal infection,
although they had been immunized three times with FA and
with 5-fold more M protein than used by us (McNamara et al.,
2008). Thus, the available data are compatible with the conclu-
sion that a good anti-HVR response requires prolonged M
protein exposure and inflammation. This conclusion implies
that many immunization regimens or infections may not result
in a protective anti-HVR response.
Collectively, our data contradict the common assumption that
the HVR of a microbial surface protein is immunodominant, and
they support the paradoxical hypothesis that an HVR may elicit
a much weaker antibody response than other parts of theer Inc.
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protein is so critical for bacterial virulence that S. pyogenes
escapes antibodies to this region by employing at least two
mechanisms, acting at different stages of an infection. During
the establishment of an infection, antigenic variation allows the
bacteria to escape attack by any pre-existing anti-HVR anti-
bodies, but antigenic variation cannot be exploited for evasion
of antibodies elicited in the newly infected host, because the M
protein is remarkably stable during an infection. However, the
weak immunogenicity of the HVR in the new host should delay
the appearance of protective antibodies and prolong the infec-
tion, thereby enhancing chances for bacterial transmission to
new hosts. Thus, a single bacterial surface protein, the M protein
of S. pyogenes, evades the adaptive immune response by two
independent mechanisms.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Culture Conditions
S. pyogenes strain M5 Manfredo (Miller et al., 1988), isolated from a patient
with rheumatic fever, was from M.A. Kehoe. The reference M1 strain
S. pyogenes SF370 (Ferretti et al., 2001) was from ATCC (Rockville, MD).
The M1 isolate MGAS5005, isolated from the cerebrospinal fluid of a patient,
was from J.M. Musser (Sumby et al., 2005). All strains were grown without
shaking in Todd-Hewitt broth supplemented with 0.2% yeast extract (THY)
in 5% CO2 at 37
C.
Proteins
The M5 protein was purified from a plasmid-carrying E. coli strain, essentially
as described (Stenberg et al., 1994). This protein had the same N-terminal
sequence as M5 expressed in S. pyogenes, because the signal sequence is
cleaved off also in E. coli. All other constructs were isolated as GST fusions
(Amersham, Swansea, UK), and after removal of theGSTmoiety, they included
the N-terminal sequence GPLGS, not present in the original protein. For PCR
amplification of DNA encodingM protein regions, we used DNA from strain M5
Manfredo or strain M1 SF370. The region encoding the M1-HVR was also
amplified from strain MGAS5005. The DNA fragment encoding the N-terminal
B6 region of the S. agalactiae b protein was amplified from strain SB35 (Hede´n
et al., 1991). The construct encoding the NN protein, derived from the
N-terminal regions of the S. agalactiae Rib and a proteins, has been described
(Sta˚lhammar-Carlemalm et al., 2007). The relevant chromosomal regions were
amplified with the primers listed in Table S1, and the DNA sequences of all
constructs were verified. Determination of N-terminal sequences by Edman
degradation was performed at the Protein Analysis Center, Karolinska Institu-
tet, Stockholm.
Animal and Human Antisera
Mice were immunized s.c. with 20 mg protein, boosted after 4 weeks with
10 mg, and bled 2 weeks later, unless otherwise stated. The mouse strain
used was C3H/HeN, except for the immunizations reported in Figures S4C–
S4D, which employed C57BL/6 mice. Adjuvants were used, as indicated.
For use of FA, the first dose and the booster were administered with complete
FA (CFA) and incomplete FA (IFA), respectively. Antisera from mice infected
with a sublethal dose of S. pyogenes M5 were recovered from mice injected
i.p. 4 weeks earlier with 106 cfu. Rabbit antisera were raised by s.c. immuniza-
tion with 100 mg protein in CFA, followed by two 50 mg boosters in IFA. The
rabbit antisera against the B6 and NN proteins have been described (Hede´n
et al., 1991; Sta˚lhammar-Carlemalm et al., 2007).
Paired antisera from humans with invasive S. pyogenes M1 infection were
obtained from six patients included in a placebo group in a study of intrave-
nous IgG therapy (Darenberg et al., 2003). These patients had received
i.v. clindamycin in combination with i.v. benzylpenicillin at inclusion in the
study. The acute serum was obtained at day 1 and the convalescent serum
at day 28 after inclusion. For each patient, the corresponding S. pyogenes
M1 strain, isolated from a blood culture, was available for analysis. The twoCell Hospatients studied in detail here were 53 and 39 years old, respectively. The
study was approved by the regional ethics committee and the drug agency
authority in Sweden. Written informed consent was obtained from all subjects
or their legal guardians.
Binding Tests with Antibodies, Optimization of Antibody Detection,
and Inhibition Tests
Binding tests were performed essentially as described (Sta˚lhammar-Carle-
malm et al., 1993; Persson et al., 2006). Microtiter wells were coated overnight
at 4C, using pure proteins at concentrations determined in preliminary tests to
give optimal results. Bound rabbit antibodies were detected with radiolabeled
protein G, while bound mouse or human antibodies were detected by incuba-
tion with secondary antibodies (rabbit anti-mouse Ig and rabbit anti-human Ig,
respectively [DakoCytomation, Denmark]) and protein G. Binding was calcu-
lated in percent of protein G bound at the lowest antiserum dilution. For
mice and rabbits, background values obtained with sera from mock-immu-
nized animals were subtracted.
To ensure that antibodies to the HVR or BCW of an M protein were detected
with similar sensitivity, whether the region studied was present in the intact
M protein or tested as an isolated fragment, experiments were performed to
optimize the test system (Figures S3A–S3D). For analysis of fusion proteins
(Figures 6 and S4), wells were coated with 25 ng M5-HVR or an equimolar
amount of the other proteins analyzed.
For inhibition assays, antiserum was incubated for 0.5 hr with the inhibiting
protein in a volume of 100 ml. The sample was then analyzed for remaining
binding activity, as described for binding tests. Coating amounts and anti-
serum dilutions were optimized for each individual assay.
Phagocytosis Assays
The assays were performed essentially as described (Carlsson et al., 2003),
using hirudin as anticoagulant and freshly drawn human blood from nonim-
mune donors, i.e., blood allowing rapid growth of the M5- and M1-expressing
strains. After rotation at 37C for 3 hr, the increase in titer (‘‘multiplication
factor’’) was calculated for each sample. Growth is plotted in a log scale and
expressed relative to the preimmune control, defined as 100. The multiplica-
tion factor for the controls varied from 133 to 347.
Protection Experiments in Mice
For analysis of passive protection against lethal infection, C3H/HeNmice were
passively vaccinated with rabbit antiserum and challenged i.p. with an LD90
dose (5 3 107 cfu) of exponentially growing M5 Manfredo bacteria. The rabbit
antiserum (100 ml) was administered twice, 4 hr before the challenge and
together with the challenge. Preliminary experiments indicated that adminis-
tration of rabbit antiserum at these two time points conferred better protection
than administration at only one of the time points. Control mice received pre-
immune serum.
For analysis of active or passive protection against bacterial growth in
organs, vaccinated C3H/HeN mice were challenged with a sublethal dose
(5 3 106 cfu) of strain M5 Manfredo. Actively immunized mice received M5
protein and FA, while passively immunized mice received rabbit antiserum,
as described above. The mice were sacrificed after 20 hr, when spleens
and/or livers were homogenized and analyzed for presence of bacteria. All
animal experiments were approved by the regional review board on animal
studies.
Other Methods
Radiolabeling, SDS-PAGE in 15% gels, western blots, dot blot analysis, and
binding tests with whole bacteria were performed essentially as described
(Sta˚lhammar-Carlemalm et al., 1993; Persson et al., 2006). In western blots,
bound rabbit antibodies were detected by incubation with radiolabeled protein
G, followed by autoradiography, while bound mouse and human antibodies
were detected by incubation with rabbit anti-mouse and rabbit anti-human
Ig, respectively, followed by radiolabeled protein G.
Statistical Analysis
In studies of passive vaccination against lethal infection (Figure 2A), Fisher’s
exact test was used to calculate p values. For the analysis of protection against
bacterial growth in organs (Figures 2B and S3E), the Coin package (Hothornt & Microbe 10, 147–157, August 18, 2011 ª2011 Elsevier Inc. 155
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Antibody Escape in a Hypervariable Regionet al., 2008) in software Rwas used to perform exact Kruskal-Wallis ANOVA on
ranks to compare the numbers of cfu. Post hoc analyses of all pairwise
comparisons were performed using the Nemenyi-Damico-Wolfe-Dunn proce-
dure if a significant result was obtained in the global test. Significance was
defined as ***p < 0.001 and **p < 0.01.
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